^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
flonoltinib
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Baoling Bio
Drug class:
JAK2 inhibitor, FLT3 inhibitor, CDK6 inhibitor
Related drugs:
3d
An open-label, positive drug-controlled, parallel-group, multicenter phase II clinical trial on the efficacy, safety and pharmacokinetics of flonoltinib maleate tablet in patients with intermediate and high-risk myelofibrosis (ChiCTR2500115640)
P2, N=75, Completed, Institute of Hematology, Chinese Academy of Medical Sciences / West China Hospital of Sichuan University; Chengdu Zenitar Biomedical Technology Co., L
New P2 trial
|
flonoltinib
3d
Phase IIa study on the safety and efficacy of Flonoltinib Maleate Tablets in the treatment of patients with polycythemia vera (ChiCTR2500111413)
P2, N=60, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University;Shengjin
New P2 trial
|
hydroxyurea • flonoltinib
3d
Food Effect Study in Healthy Volunteers of Phase I Flonoltinib Maleate (ChiCTR2500115039)
P1, N=24, Completed, Chengdu Xinhua Hospital; Chengdu Zenitar Biomedical Technology Co.Ltd.
New P1 trial
|
flonoltinib
28d
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (clinicaltrials.gov)
P3, N=105, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
New P3 trial
|
Jakafi (ruxolitinib) • flonoltinib
3ms
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (clinicaltrials.gov)
P2, N=60, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
New P2 trial • Tumor mutational burden
|
hydroxyurea • flonoltinib
4ms
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative (clinicaltrials.gov)
P1/2, N=31, Completed, Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2025
Trial completion • Trial completion date
|
flonoltinib
4ms
A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets (clinicaltrials.gov)
P1, N=24, Completed, Chengdu Zenitar Biomedical Technology Co., Ltd
New P1 trial
|
flonoltinib
5ms
A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects (clinicaltrials.gov)
P1, N=40, Completed, Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting --> Completed
Trial completion
|
flonoltinib
over1year
Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial (clinicaltrials.gov)
P2, N=75, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
New P2 trial
|
Jakafi (ruxolitinib) • flonoltinib
2years
Study on tissue distribution, metabolite profiling, and excretion of [C]-labeled flonoltinib maleate in rats. (PubMed, J Pharm Biomed Anal)
A minor fraction of FM (<10 %) was excreted through renal excretion in the form of urine. Integration of the current results with previous pharmacokinetic investigations of FM in rats and dogs enables a comprehensive elucidation of the in vivo ADME processes and characteristics of FM, thereby establishing a solid foundation for subsequent clinical investigations of FM.
Preclinical • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • JAK2 (Janus kinase 2)
|
flonoltinib
almost3years
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection (clinicaltrials.gov)
P=N/A, N=66, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
New trial
|
IL6 (Interleukin 6)
|
flonoltinib
Share via
